Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

This study has been completed.
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
MedImmune LLC
ClinicalTrials.gov Identifier:
NCT01579916
First received: April 16, 2012
Last updated: December 16, 2013
Last verified: December 2013
  Purpose

This prospective annual release study was designed to assess the safety of a trivalent influenza virus vaccine using two new strains recommended for the 2012-2013 influenza season not previously contained in the trivalent intranasal FluMist vaccine.

Three hundred healthy adults will receive a single dose of vaccine or placebo and will be followed for 180 days after study vaccination.


Condition Intervention Phase
Influenza
Biological: Trivalent Influenza Virus Vaccine
Other: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Resource links provided by NLM:


Further study details as provided by MedImmune LLC:

Primary Outcome Measures:
  • Percentage of Participants Reporting Fever Within 7 Days Post Vaccination [ Time Frame: Study Days 1 - 8 ] [ Designated as safety issue: Yes ]
    A comparison of the rate of fever, defined as oral temperature greater than or equal to 101 degrees Fahrenheit, reported during the 7 days post administration of investigational product between the trivalent influenza virus vaccine and placebo groups.


Secondary Outcome Measures:
  • Percentage of Participants Reporting Other Solicited Symptoms Within 7 Days Post Vaccination [ Time Frame: Study Days 1- 8 ] [ Designated as safety issue: Yes ]
    Solicited symptoms were events that were considered likely to occur post dosing. Solicited symptoms for this study are listed below.

  • Percentage of Participants Reporting Any Adverse Event (AE) Within 7 Days Post Vaccination [ Time Frame: Study Days 1 - 8 ] [ Designated as safety issue: Yes ]
    Percentage of participants reporting at least one AE between Days 1 and 8. Investigational product was administered on Day 1.

  • Percentage of Participants Reporting Other Solicited Symptoms Within 14 Days Post Vaccination [ Time Frame: Study Days 1 - 15 ] [ Designated as safety issue: Yes ]
    Solicited symptoms were events that were considered likely to occur post dosing. Solicited symptoms for this study are listed below.

  • Percentage of Participants Reporting Any Adverse Event (AE) Within 14 Days Post Vaccination [ Time Frame: Study Days 1 - 15 ] [ Designated as safety issue: Yes ]
    Percentage of participants reporting at least one AE between Days 1 and 15. Investigational product was administered on Day 1.

  • Percentage of Participants Reporting Any Serious Adverse Event (SAE) Within 28 Days Post Vaccination [ Time Frame: Study Days 1 - 29 ] [ Designated as safety issue: Yes ]
    Percentage of participants reporting at least one SAE between Days 1 and 29. Investigational product was administered on Day 1.

  • Percentage of Participants Reporting Any Serious Adverse Event (SAE) Within 180 Days Post Vaccination [ Time Frame: Study Days 1 - 181 ] [ Designated as safety issue: Yes ]
    Percentage of participants reporting at least one SAE between Days 1 and 181. Investigational product was administered on Day 1.

  • Percentage of Participants Reporting Any New Onset Chronic Diseases (NOCDs) Within 28 Days Post Vaccination [ Time Frame: Study Days 1 - 29 ] [ Designated as safety issue: Yes ]
    An NOCD was a newly diagnosed medical condition of a chronic, ongoing nature and assessed by the investigator as medically significant. Such events were assessed between Day 1 and Day 29. Investigational product was administered on Day 1.

  • Percentage of Participants Reporting Any New Onset Chronic Diseases (NOCDs) Within 180 Days Post Vaccination [ Time Frame: Study Days 1 - 181 ] [ Designated as safety issue: Yes ]
    An NOCD was a newly diagnosed medical condition of a chronic, ongoing nature and assessed by the investigator as medically significant. Such events were assessed between Day 1 and Day 181. Investigational product was administered on Day 1.

  • Percentage of Participants Who Used Antipyretic or Analgesic Agents Within 7 Days Post Vaccination [ Time Frame: Study Days 1 - 8 ] [ Designated as safety issue: Yes ]
    Percentage of participants who used an antipyretic or analgesic agent between Days 1 and 8. Investigational product administration occurred on Day 1.

  • Percentage of Participants Who Used Antipyretic or Analgesic Agents Within 14 Days Post Vaccination [ Time Frame: Study Days 1 - 15 ] [ Designated as safety issue: Yes ]
    Percentage of participants who used an antipyretic or analgesic agent between Days 1 and 15. Investigational product administration occurred on Day 1.


Enrollment: 303
Study Start Date: May 2012
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Trivalent Influenza Virus Vaccine
Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.
Biological: Trivalent Influenza Virus Vaccine
Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.
Placebo Comparator: Placebo
Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.
Other: Placebo
Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.

Detailed Description:

This prospective, randomized, double-blind, placebo-controlled release study will enroll approximately 300 healthy adults 18 to 49 years of age. Eligible subjects will be randomly assigned in a 4:1 fashion to receive a single dose of trivalent vaccine or placebo by intranasal spray. Randomization will be stratified by site.

This study will be conducted at 3 sites in the United States of America. Each subject will receive one dose of investigational product on Study Day 1. The duration of study participation for each subject is the time from study vaccination through 180 days after study vaccination.

  Eligibility

Ages Eligible for Study:   18 Years to 49 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Age 18 through 49 years at the time of investigational product administration
  2. Written informed consent and any locally required authorization (ie, HIPAA in the USA) obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations
  3. Females of childbearing potential who are sexually active with a nonsterilized male partner must use effective contraception for 30 days prior to study vaccination, and must agree to continue using such precautions for 60 days after study vaccination
  4. Nonsterilized males who are sexually active with a female partner of child-bearing potential must use an effective method of contraception from prior to study vaccination amd must agree to continue using such precautions for at least 30 days after receipt study vaccination
  5. Healthy by medical history and physical examination
  6. Female subjects of child-bearing potential must also have a negative urine or blood pregnancy test at screening and, if screening and Day 1 do not occur on the same day, on the day of vaccination prior to randomization.
  7. Subject available by telephone
  8. Ability to understand and comply with the requirements of the protocol, as judged by the investigator
  9. Ability to complete follow-up period of 180 days after dosing as required by the protocol

Exclusion Criteria:

  1. Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results
  2. Concurrent enrollment in another clinical study up to 180 days after receipt of investigational product (Day 181)
  3. Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals
  4. History of hypersensitivity to any component of the vaccine, including egg or egg protein or serious, life threatening, or severe reactions to previous influenza vaccinations
  5. History of hypersensitivity to gentamicin
  6. Any condition for which the inactivated influenza vaccine is indicated, including chronic disorders of the pulmonary or cardiovascular systems (eg, asthma), chronic metabolic diseases (eg, diabetes mellitus), renal dysfunction, or hemoglobinopathies that required regular medical follow-up or hospitalization during the preceding year
  7. Acute febrile (> 100.0°F oral or equivalent) and/or clinically significant respiratory illness (eg, cough or sore throat) within 14 days prior to randomization
  8. Any known immunosuppressive condition or immune deficiency disease, including human immunodeficiency virus infection, or ongoing immunosuppressive therapy
  9. History of Guillain-Barré syndrome
  10. A household contact who is severely immunocompromised (eg, hematopoietic stem cell transplant recipient, during those periods in which the immunocompromised individual requires care in a protective environment); additionally, subject should avoid close contact with severely immunocompromised individuals for at least 21 days after study vaccination
  11. Receipt of any investigational agent within 30 days prior to randomization, or expected receipt through 30 days after study vaccination (use of licensed agents for indications not listed in the package insert is permitted)
  12. Receipt of any non-study vaccine within 30 days prior to randomization, or expected receipt through 30 days after study vaccination
  13. Expected receipt of antipyretic or analgesic medication on a daily or every other day basis from randomization through 14 days after study vaccination
  14. Administration of intranasal medications within 14 days prior to randomization, or expected receipt through 14 days after study vaccination
  15. Receipt of influenza antiviral therapy or antiviral agents within 48 hours prior to study vaccination or expected receipt of influenza antiviral therapy or antiviral agents through 14 days after study vaccination
  16. Known or suspected mitochondrial encephalomyopathy
  17. Nursing mother
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01579916

Locations
United States, Florida
Research Site
Miami, Florida, United States, 33143
United States, Georgia
Research Site
Stockbridge, Georgia, United States, 30281
United States, Oregon
Research Site
Portland, Oregon, United States, 97239
Sponsors and Collaborators
MedImmune LLC
AstraZeneca
Investigators
Study Director: Raburn Mallory, MD MedImmune LLC
  More Information

No publications provided

Responsible Party: MedImmune LLC
ClinicalTrials.gov Identifier: NCT01579916     History of Changes
Other Study ID Numbers: CD-VA-FluMist-1114
Study First Received: April 16, 2012
Results First Received: December 16, 2013
Last Updated: December 16, 2013
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by MedImmune LLC:
Trivalent, Influenza, FluMist, Vaccine, Prevention

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Respiratory Tract Diseases
Respiratory Tract Infections
Virus Diseases

ClinicalTrials.gov processed this record on November 20, 2014